Drugs / XoGlo Pro
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07664696 Comparator | Jan 2027 → Jun 2028 expected | COVID-19 | Kimera Labs Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XoGlo Pro | “Single IV infusion of the drug product XoGlo Pro” NCT07664696 ↗ |
| Modality | Other / unclassified | “placental, mesenchymal stem cell-derived extracellular vesicles” NCT07664696 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT07664696 ↗ |